Cannabis Market in Australia

Australia legalized medical cannabis at the federal level in 2016 through the Narcotic Drugs Amendment Act, and the market has grown steadily since. The Therapeutic Goods Administration (TGA) oversees the prescribing framework, with patients accessing cannabis through the Special Access Scheme (SAS-B) or through Authorised Prescribers. The number of SAS-B approvals has grown exponentially, from a few hundred in 2017 to over 500,000 cumulative approvals, reflecting increasing physician and patient comfort with cannabis-based treatments.

The Australian market is distinctive for its strong emphasis on pharmaceutical-grade quality and its position as a potential export hub. The Office of Drug Control (ODC) issues cultivation and manufacturing licenses, and Australian-produced cannabis must meet strict TGA standards. Several Australian companies have positioned themselves as premium cultivators targeting both the domestic market and export to markets like Germany, the UK, and Southeast Asia. The country's established pharmaceutical manufacturing infrastructure and regulatory credibility provide competitive advantages in quality-sensitive international markets.

In 2020, the Australian Capital Territory (ACT) became the first Australian jurisdiction to decriminalize personal cannabis possession and home cultivation for adults. While this applies only to the ACT (population ~450,000), it marked a significant shift in the national conversation. Other states and territories have not followed suit, and recreational cannabis remains illegal across the rest of Australia. However, the medical market's rapid growth suggests increasing social acceptance that could eventually support broader legalization efforts.

The Australian cannabis industry includes both ASX-listed companies and companies listed on overseas exchanges. Notable Australian cannabis companies include Little Green Pharma, Althea Group (now Peak Processing Solutions), Cann Group, and Elixinol Global. Many of these companies have focused on building cultivation capacity, obtaining necessary licenses, and establishing distribution partnerships with pharmacies. The industry has faced challenges common to early-stage cannabis markets, including slow patient growth in the early years, regulatory complexity, and the capital requirements of building GMP-certified production facilities.